Viatris Inc. vs Supernus Pharmaceuticals, Inc.: A Gross Profit Performance Breakdown

Pharma Giants' Profit Battle: Viatris vs Supernus

__timestampSupernus Pharmaceuticals, Inc.Viatris Inc.
Wednesday, January 1, 20141162870003669400000
Thursday, January 1, 20151360040004382200000
Friday, January 1, 20162030170004998500000
Sunday, January 1, 20172870230004976200000
Monday, January 1, 20183935410004572000000
Tuesday, January 1, 20193760950004444200000
Wednesday, January 1, 20204679380003796700000
Friday, January 1, 20215047140005575500000
Saturday, January 1, 20225800170006497000000
Sunday, January 1, 20235237420006438600000
Loading chart...

Unlocking the unknown

A Tale of Two Pharmaceutical Giants: Viatris Inc. vs Supernus Pharmaceuticals, Inc.

In the ever-evolving pharmaceutical industry, understanding the financial health of companies is crucial. This analysis delves into the gross profit performance of Viatris Inc. and Supernus Pharmaceuticals, Inc. over the past decade, from 2014 to 2023.

Viatris Inc. consistently outperformed Supernus Pharmaceuticals, with an average gross profit nearly 13 times higher. Notably, Viatris saw a significant surge in 2022, reaching a peak gross profit of approximately $6.5 billion, a 75% increase from 2014. Meanwhile, Supernus Pharmaceuticals experienced steady growth, peaking in 2022 with a gross profit of around $580 million, a fivefold increase from 2014.

This comparison highlights the dynamic nature of the pharmaceutical sector, where strategic mergers and innovative product lines can dramatically influence financial outcomes.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025